Glen Doherty

UCD Full Clinical Professor

Dublin City University

Ireland

Research Interests

Explore related searches

Professors in Ireland Professors in Immunology Immunology professors in Ireland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Glen Doherty is a Full Clinical Professor at University College Dublin, Ireland. His research primarily focuses on inflammatory bowel disease, including the efficacy of various treatments and biomarkers associated with gastrointestinal disorders. Recent publications include studies on the prevalence of inflammatory bowel disease in patients with hidradenitis suppurativa and advancements in endoscopic performance. He is also actively involved in exploring the implications of genetic and epigenetic factors in pediatric ulcerative colitis.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (25)

Henit Yanai

ISRAEL

Glen Doherty

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial.

Inflammatory Bowel Disease Prevalence in Patients with Hidradenitis Suppurativa Using Prospective Symptom-Based Questionnaires and Fecal Calprotectin Testing

Sustained success in endoscopic performance demonstrated by the Irish National Endoscopy Quality Improvement Programme.

Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus

HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease

Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant‐treated rectal adenocarcinoma

Neoplasia detection in FIT positive screening colonoscopies compared with an age-controlled symptomatic cohort: a retrospective review

Inflammatory Bowel Disease Disability Index is a valid and reliable measure of disability in an English-speaking hospital practice and predicts long-term requirement for treatment escalation

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.

Multiomic Sequencing Reveals Distinctive Gene Expression and Epigenetic Alterations Associated With Primary Sclerosing Cholangitis Development in Treatment-Naïve Pediatric Ulcerative Colitis.

Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease.

Caspase-4 Has Potential Utility as a Colorectal Tissue Biomarker for Dysplasia and Early-Stage Cancer.

The effects of dairy on the gut microbiome and symptoms in gastrointestinal disease cohorts: a systematic review.

Reduced serological response to COVID-19 booster vaccine is associated with reduced B cell memory in patients with Inflammatory Bowel Disease; VARIATION (VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON).

Butyrate limits human natural killer cell effector function.

The Tortoise (Endoscopy-Driven Treatment) and the Hare (Prophylactic Treatment): Who Wins the Race to Beat Post-Operative Recurrence of Crohn's Disease?

A stalk with no polyp-A muco-submucosal elongated polyp in the duodenum.

Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata

Implementation of BSG/ACPGBI/PHE polypectomy surveillance guidelines safely reduces the burden of surveillance in a screening cohort: a virtual model study

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

The Associations of Selenoprotein Genetic Variants with the Risks of Colorectal Adenoma and Colorectal Cancer: Case–Control Studies in Irish and Czech Populations

Reduced serological response to COVID-19 vaccines in patients with IBD is further diminished by TNF inhibitor therapy; Early results of the VARIATION study (VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON)

The Trypanosoma brucei-Derived Ketoacids, Indole Pyruvate and Hydroxyphenylpyruvate, Induce HO-1 Expression and Suppress Inflammatory Responses in Human Dendritic Cells

Faecal calprotectin as a potential biomarker of disease severity in SARS-CoV-2 infection

Collaborators (25)

Henit Yanai

Javier Pérez Gisbert

Virginie Gautier

David J. Hughes

Rachel Cooney

NOEMI MANCEÑIDO MARCOS

aisling dunne

Flavio Caprioli

Triana Lobaton Ortega

Derek Nolan

Jayne Doherty

Emma Creagh

MARIA ESTEVE

Ann-Sofie Backman

Dmitri Wall

Gordon Moran

Ingrid Ordas

Gerard Cagney

Elizabeth Ryan

Conor Costigan

Julien Kirchgesner

Jean Fletcher

Michael Schultz

Mette Julsgaard

Pavel Vodička

Make your next move.